[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients

European Journal of Nuclear Medicine - Tập 33 Số 12 - Trang 1387-1398 - 2006
M. Cimitan1, Roberto Bortolus2, Sandro Morassut3, Vincenzo Canzonieri4, A. Garbeglio5, Tanja Baresic1, Eugenio Borsatti1, A. Drigo6, M. Trovò2
1Department of Nuclear Medicine, National Cancer Institute–CRO Aviano (IRCCS), Aviano (PN), Italy
2Department of Radiotherapy, National Cancer Institute–CRO Aviano, Aviano (PN), Italy
3Department of Radiology, National Cancer Institute–CRO Aviano, Aviano (PN), Italy
4Department of Pathology, National Cancer Institute–CRO Aviano, Aviano (PN), Italy
5Department of Urology, Hospital S Maria degli Angeli, Pordenone (PN), Italy
6Medical Physics Unit, National Cancer Institute–CRO Aviano, Aviano (PN), Italy

Tóm tắt

Từ khóa


Tài liệu tham khảo

Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20:207–223

Loblaw A, Mendelson D, Talcott J, Virgo K, Somerfield M, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927–2941

Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am 1991;18:15–24

Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A sub analysis of EORTC trial 30853. The EORTC Urological Group. Cancer 1990;66:1009–1016

Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996;48:594–599

Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38:59–85

Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000;38:115–138

Nudell DM, Wefer AE, Hricak H, Caroll PR. Imaging for recurrent prostate cancer. Radiol Clin North Am 2000;38:213–229

May F, Treumann T, Dettmar P, Hartung R, Breul J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 2001;87:66–69

Hricak H, Schoder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, et al. Advances in imaging in the postoperative patients with a rising prostate-specific antigen level. Semin Oncol 2003;30:616–634

Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, et al. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Group. J Urol 1998;159:2041–2046

Cher M, Bianco F Jr, Lam J, Davis L, Grignon D, Sakr W, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387–1391

Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632–1642

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576–581

Dotan Z, Bianco F, Rabbani F, Easthman J, Fearn P, Scher H, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23:1962–1968

Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrum A. Positron emission tomography in urological oncology. J Urol 1998;159:347–356

Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31–35

Liu IJ, Zafar MB, Lai YH, Segall GM, Terri MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108–111

Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990–995

Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinshmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27;1415–1419

De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002;42:18–23

Coleman R, De Grado T, Wang S, Baldwin S, Orr M, Reiman R, et al. Preliminary evaluation of F-18 Fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000;3:147

Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549–555

De Grado T, Coleman R, Wang S, Baldwin S, Orr M, Robertson C, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110–117

Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274–292

Seltzer M, Jahan S, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, et al. Radiation dose estimates in humans for 11C-acetate whole-body PET. J Nucl Med 2004;45:1233–1236

De Grado T, Reiman R, Price D, Wang S, Coleman R. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002;43:92–96

Schmid D, John H, Zweifel R, Cservenyak T, Westera G, Goerres G, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623–628

Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337–1340

De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331–335

De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32–39

Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317–324

Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005;32:742–748

Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642–1649

Hara T, Yuasa M. Automated synthesis of fluorine-18 labeled choline analogue: 2-fluoroethyl-dimethyl-2oxyethylammonium [abstract]. J Nucl Med 1997;38(suppl):44P

Hara T, Kosaka N, Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187–199

De Grado T, Baldwin R, Wang S, Orr M, Liao R, Friedman H, et al. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805–1814

Price D, Coleman R, Liao R, Robertson C, Polascik T, De Grado T. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273–280

Kwee S, Wei H, Sesterhenn I, Yun D, Coel M. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006;47:262–269

Freedland S, Sutter M, Dorey F, Aronson W. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy: prostate-specific antigen. Urology 2003;61:365–369